Compare · DXCM vs KIDS
DXCM vs KIDS
Side-by-side comparison of DexCom Inc. (DXCM) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 57.1x KIDS ($415.9M).
- Over the past year, DXCM is down 13.5% and KIDS is down 25.6% - DXCM leads by 12.1 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 3 for KIDS).
- DXCM has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- DexCom Inc.
- OrthoPediatrics Corp.
- Price
- $61.55-1.84%
- $16.16-0.28%
- Market cap
- $23.76B
- $415.9M
- 1M return
- -7.89%
- -0.40%
- 1Y return
- -13.51%
- -25.64%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2017
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 8
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest KIDS
- SEC Form DEF 14A filed by OrthoPediatrics Corp.
- SEC Form DEFA14A filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
- OrthoPediatrics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
- COO and CFO Hite Fred was granted 77,405 shares and sold $224,129 worth of shares (12,993 units at $17.25), increasing direct ownership by 30% to 277,477 units (SEC Form 4)
- Pres. Trauma & Def. Correction Hauser Joseph W was granted 65,700 shares and sold $148,281 worth of shares (8,596 units at $17.25), increasing direct ownership by 41% to 194,767 units (SEC Form 4)
- President and CEO Bailey David R sold $336,979 worth of shares (19,535 units at $17.25), decreasing direct ownership by 6% to 298,020 units (SEC Form 4)
- President of Scoliosis Odle Gregory A sold $145,469 worth of shares (8,433 units at $17.25) and was granted 47,380 shares, increasing direct ownership by 26% to 187,735 units (SEC Form 4)
- General Counsel and Secretary Gerritzen Daniel J was granted 47,380 shares and sold $148,592 worth of shares (8,614 units at $17.25), increasing direct ownership by 35% to 149,533 units (SEC Form 4)